Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 634

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 634
---
763 | ) |
| Inflation adjustment                |     |   18 |     |                  798,576 |   |     |    678,255 |   |
| Financial results, net              |     |      |     |                   (3,544 | ) |     |   (858,725 | ) |
| Net loss for the period             |     |      |     |               (1,322,306 | ) |     | (1,434,684 | ) |
| Basic and diluted loss per share    |     |   19 |     |                   (0.044 | ) |     |     (0.048 | ) |

The accompanying notes are an integral part of these Unaudited interim condensed Combined Financial Statements. ____________ (*)For the six -monthperiods ended December 31, 2024 and 2023, includes sales to related parties amounted to US$ 696,606 and US$ 672,336, respectively. See Note 20

F-92

OmnigenicsAI Corp
Interim condensed Combined Statements of Other Comprehensive Loss
For the six-month periods ended December 31, 2024 and 2023
(All amounts in US Dollars, except for share data and otherwise indicated)
(Unaudited)

|                                                                   |     | For the six-month period 
 ended December 31,       
 2024                     |   |     | 2023       |   |
|:------------------------------------------------------------------|:----|:-------------------------|:--|:----|:-----------|:--|
| Other comprehensive loss                                          |     |                          |   |     |            |   |
| Net loss for the period                                           |     | (1,322,306               | ) |     | (1,434,684 | ) |
| Items that may be reclassified to profit or loss                  |     |                          |   |     |            |   |
| Foreign exchange differences on translation of foreign operations |     | (200,548                 | ) |     | (11,780    | ) |
| Total other comprehensive (loss)                                  |     | (200,548                 | ) |     | (11,780    | ) |
| Total comprehensive loss for the period                           |     | (1,522,854               | ) |     | (1,446,464 | ) |

The accompanying notes are an integral part of these Unaudited interim condensed Combined Financial Statements.

F-93

Omnigen